Metraipolis › archive › dc_0b58eb079cd1

Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma — Europe PMC PMID:41972186

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41972186
DOI
10.3389/fimmu.2026.1782008
License (as archived)
solo-consultazione
Archived
2026-11-03T20:06:56.154Z
SHA-256 of the archived text
059ea64f282042d2dcb0d23116b8870a2acc80fee32fde933d98925dbf08bc45
Stable URL of this page
https://metraipolis.com/documento/dc_0b58eb079cd1

How to cite

Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma — Europe PMC PMID:41972186 — Europe PMC (en), https://europepmc.org/article/MED/41972186 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0b58eb079cd1 (Metraipolis archive dc_0b58eb079cd1, sha256 059ea64f282042d2dcb0d23116b8870a2acc80fee32fde933d98925dbf08bc45)
BibTeX
@misc{dc0b58eb079cd1,
  title = {Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma — Europe PMC PMID:41972186},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41972186},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0b58eb079cd1; sha256 059ea64f282042d2dcb0d23116b8870a2acc80fee32fde933d98925dbf08bc45},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41972186. Agents can read the archived copy with the MCP tool read_document.